The Effect of Treatment with the Complement C5a Receptor Inhibitor Avacopan on Health-Related Quality of Life in ANCA-Associated Vasculitis

Speaker(s):

• Vibeke Strand, Division of Immunology and Rheumatology, Stanford University
• Pirow Bekker, ChemoCentryx, Inc.
• Huibin Yue, ChemoCentryx, Inc.
• David R. Jayne, Department of Medicine, University of Cambridge
• Peter A. Merkel, Division of Rheumatology, University of Pennsylvania